Drug discovery is a long, complex, and costly process that often takes more than a decade and has a low success rate. According to a recent study, only about 10% of drug candidates that enter clinical trials eventually get approved by the FDA. This means that many patients with complex and hard-to-treat diseases are left without effective treatments.

But what if there was a way to accelerate drug discovery and increase the chances of finding novel and effective therapies? That’s the vision of Aria Pharmaceuticals, a preclinical-stage pharmaceutical company that is using artificial intelligence (AI) to discover and develop new small molecule drugs for various diseases.

Aria Pharmaceuticals (formerly twoXAR Pharmaceuticals) was founded in 2014 by Andrew Radin and Andrew A. Radin, two cousins who shared a passion for applying AI to biomedicine. They developed a proprietary AI platform that can rapidly screen millions of molecules against hundreds of disease models and identify potential drug candidates with high accuracy and efficiency.

The AI platform works by integrating multiple sources of data, such as genomic, proteomic, phenotypic, and clinical data, and applying advanced algorithms to learn the complex relationships between molecules and diseases. The platform can then generate novel hypotheses and rank the most promising molecules based on their predicted efficacy, safety, and pharmacokinetics.

Using this approach, Aria Pharmaceuticals has shown promise across a diverse range of therapeutic areas, such as oncology, immunology, neurology, dermatology, and rare diseases. The company has the ability to address over 1,000 diseases with its AI platform. Some of the current programs in its pipeline include:

  • TXR-311: A first-in-class small molecule inhibitor of DDX3X, a protein involved in RNA metabolism and stress response, for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.
  • TXR-1206: A novel small molecule modulator of RORγt, a transcription factor that regulates the differentiation and function of Th17 cells, for the treatment of inflammatory bowel disease (IBD), a chronic condition that affects the digestive system.
  • TXR-1508: A new small molecule inhibitor of PIM kinases, a family of enzymes that promote cell survival and proliferation, for the treatment of triple-negative breast cancer (TNBC), a highly aggressive and difficult-to-treat subtype of breast cancer.

These programs are currently in various stages of preclinical development and have demonstrated promising results in animal models. Aria Pharmaceuticals plans to advance them to clinical trials in the near future.

By leveraging AI to redefine drug discovery, Aria Pharmaceuticals aims to deliver breakthrough treatments for patients with complex and hard-to-treat diseases. The company believes that AI can not only speed up the process and reduce the costs of drug development, but also enable the discovery of new mechanisms of action and novel targets that would otherwise be missed by conventional methods.

Aria Pharmaceuticals is on a mission to transform the lives of patients with its innovative AI-powered drug discovery platform. To learn more about the company and its programs, visit its website.

Also Read: How Composable Analytics Enables Data-Driven Organizations With Intelligent DataOps